Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
DaVita Inc. (DVA)
Last davita inc. earnings: 2/10 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.davita.com/investor-relations
Company Research
Source: PR Newswire
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investorsThe collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territoryAlebund holds a substantial non-dilutive equity interest in R1, with the opportunity to participate in future commercial upside through dividendsSHANGHAI, March 17, 2026 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a leading renal-focused biopharmaceutical company, today announced that it has entered into licensing and
Show less
Read more
Impact Snapshot
Event Time:
DVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVA alerts
High impacting DaVita Inc. news events
Weekly update
A roundup of the hottest topics
DVA
News
- Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306PR Newswire
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney diseaseGlobeNewswire
- Are Investors Undervaluing DaVita (DVA) Right Now? [Yahoo! Finance]Yahoo! Finance
- DaVita tops chart as the only large-cap healthcare services name rated Strong Buy [Seeking Alpha]Seeking Alpha
DVA
Earnings
- 2/2/26 - Beat
DVA
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- DVA's page on the SEC website